Healthcare Review: Aratana Therapeutics, BSD Medical, Xencor, CombiMatrix, Acadia Pharmaceuticals Print E-mail
By Staff and Wire Reports   
Tuesday, 15 July 2014 13:56
U.S. stocks fell on Tuesday after Federal Reserve Chairwoman Janet Yellen expressed concern about valuations in some corners of the market. In prepared testimony, Ms. Yellen singled out small-company stocks, as well as biotechnology and social-media shares as appearing to be "stretched." Those comments overshadowed what traders said was otherwise friendly testimony for the stock market, with Ms. Yellen suggesting the Fed is in no rush to raise interest rates. The Dow Jones Industrial Average recently fell 31 points, or 0.2%, to 17024 after rallying to an intraday high of 17120.34 earlier.

Aratana Therapeutics ($PETX) files an S-3 for a $100M mixed shelf offering plus the registration of 500,000 shares of common stock for sale by Avalon Ventures.

BSD Medical ($BSDM) initiates a 28-patient Phase 1/2 clinical trial evaluating the use of hyperthermia combined with proton radiotherapy as a treatment for patients with unresectable soft tissue sarcoma. Investigators will use the company's BSD-2000 System or BSD-500 System to deliver the hyperthermia. The systems deliver localized therapeutic heating by applying radiofrequency (RF) energy.

Xencor ($XNCR) promotes VP of Research John R. Desjarlais, Ph.D., to SVP of Research and Chief Scientific Officer. He joined the company in 2001 and was promoted to VP of Research in 2006.

The New York Department of Public Health grants conditional approval for CombiMatrix's (NASDAQ:CBMX) chromosomal microarray CombiSNP Array for Pediatric Analysis for testing patient samples. The American College of Medical Genetics recommends the test for pediatric development disorders to determine if genetic defects are a factor. Under conditional approval, the company will be able to market the test in NY while the test is under Clinical Laboratory Reference System review. Upon the completion of the review, the test will receive full marketing approval (if additional information is not required).

Acadia Pharmaceuticals (NASDAQ:ACAD) hires Stephen Davis as EVP, CFO and Chief Business Officer reporting to CEO Uli Hacksell, Ph.D. Mr. Davis joins the company from Heron Therapeutics where he was EVP and COO.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter